Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

GeneDx Holdings (WGS) Cash & Equivalents (2020 - 2025)

Historic Cash & Equivalents for GeneDx Holdings (WGS) over the last 6 years, with Q3 2025 value amounting to $96.0 million.

  • GeneDx Holdings' Cash & Equivalents rose 6576.5% to $96.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $96.0 million, marking a year-over-year increase of 6576.5%. This contributed to the annual value of $85.2 million for FY2024, which is 1451.53% down from last year.
  • As of Q3 2025, GeneDx Holdings' Cash & Equivalents stood at $96.0 million, which was up 6576.5% from $74.1 million recorded in Q2 2025.
  • Over the past 5 years, GeneDx Holdings' Cash & Equivalents peaked at $461.3 million during Q3 2021, and registered a low of $26.5 million during Q2 2021.
  • For the 5-year period, GeneDx Holdings' Cash & Equivalents averaged around $155.8 million, with its median value being $99.7 million (2023).
  • Its Cash & Equivalents has fluctuated over the past 5 years, first surged by 4036355.24% in 2021, then tumbled by 6906.08% in 2022.
  • Quarter analysis of 5 years shows GeneDx Holdings' Cash & Equivalents stood at $400.6 million in 2021, then crashed by 69.06% to $123.9 million in 2022, then fell by 19.57% to $99.7 million in 2023, then decreased by 14.52% to $85.2 million in 2024, then rose by 12.62% to $96.0 million in 2025.
  • Its last three reported values are $96.0 million in Q3 2025, $74.1 million for Q2 2025, and $99.7 million during Q1 2025.